Philina Lee: Yes, sure, Derek. I think at the heart of your question. Your first question is really about has the advanced SM opportunity peaked for what is sort of the headroom on that. So to be really clear, we see headroom significantly to continue to grow the advanced SM opportunity. We know that this is going to happen at a more measured rate than the growth trajectory that we saw early in the launch. And that growth is driven by several factors. We’re still early in penetrating into the overall advanced SM patient population. We are the standard of care in the treated patient population, but the biggest lever of growth is truly activating the fuller breadth of advanced SM patients to be treated for their SM. And so penetration across all subtypes, significant room to continue expanding on the breadth and depth of the prescriber base, as well as the durations of therapy, which are favorable.
And as we shift towards a more treatment-naive patient population, that is also a favorable harbinger of longer durations of therapy over extended periods of time. So to your second question about the 400 patients. So just to be really clear, that is just the moderate to severe ISM patients who are treated by the top 350 of our current prescriber base. And importantly, we know that it’s important to engage a broader prescriber base who are treating that 7,500 moderate to severe ISM patients who are diagnosed and actively seeking treatment today. So when we think about where early adoption of AYVAKIT could happen post ISM approval, we see it not only among those 400 patients treated by the current top volume prescribers, but also among that broader group of patients who really have severe symptomology.
Derek Archila: Got it. Thank you.
Operator: Our next question comes from Ana Macdonald from Goldman Sachs. Please go ahead.
Unidentified Analyst: Good morning. This is Ana Macdonald on for Salveen. Thank you for taking our question. So on the ISM launch, we’re just trying to understand what patients would be the early adopters. So from the 400 patients that you mentioned, what proportion would not be well controlled on current treatments? And then just quickly on the CDK2 program, with your proposed actions, is the FDA aligned on the changes to the protocol? Thank you.
Kate Haviland: So thank you for that question. Maybe we’ll start with the overall numbers of ISM. I think we’re getting a little bit confused on the 400. So I just want to make that really clear for people. So maybe, Christy, can take that. And then Becker, if you could take the CDK2. Yeah, go ahead.
Christy Rossi: Yes, happy to. So both of the last two questions, I think, are getting a little bit to sort of where the patients are in breadth and depth. So just to be clear on the 400, we see 400 moderate-to-severe, not well-controlled ISM patients amongst physicians who currently have AYVAKIT experience. So I think that gets to the earlier question on overlap as well. So I think the overall idea here is that there’s a lot of potential with ISM amongst prescribers who have current AYVAKIT experience. And certainly, early in the launch, that is a place that we will focus to drive growth. The 7,500 patients in total when we throw that number out and talk about that, all of those patients are patients that we view to be moderate to severe, not well controlled and candidates for therapy.
